Lufyllin-EPG (dyphylline / ephedrine / guaifenesin / phenobarbital) and Alcohol / Food Interactions
There are 3 alcohol/food/lifestyle interactions with Lufyllin-EPG (dyphylline / ephedrine / guaifenesin / phenobarbital) which include:
PHENobarbital ↔ Alcohol (Ethanol)
Major Drug Interaction
Ask your doctor before using PHENobarbital together with ethanol, this can add to dizziness, drowsiness and other side effects of PHENobarbital. Be careful if you drive or do activities that require you to be awake and alert. Talk with your doctor before using any medications together, or drinking alcohol with PHENobarbital. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
ePHEDrine ↔ Alcohol (Ethanol)
Minor Drug Interaction
Consumer information for this minor interaction is not currently available. Some minor drug interactions may not be clinically relevant in all patients. Minor drug interactions do not usually cause harm or require a change in therapy. However, your healthcare provider can determine if adjustments to your medications are needed.
For clinical details see professional interaction data.
High Blood Pressure (Hypertension)
Severe Potential Hazard, Moderate plausibility
barbiturates IV - cardiovascular
The intravenous administration of barbiturates may produce severe cardiovascular reactions such as bradycardia, hypertension, or vasodilation with fall in blood pressure, particularly during rapid infusion. Parenteral therapy with barbiturates should be administered cautiously in patients with hypertension, hypotension, or cardiac disease. The intravenous administration of barbiturates should be reserved for emergency treatment of acute seizures or for anesthesia.
- "Product Information. Amytal Sodium (amobarbital)" Lilly, Eli and Company, Indianapolis, IN.
- "Product Information. Phenobarbital (phenobarbital)." Lilly, Eli and Company, Indianapolis, IN.
- "Product Information. Seconal Sodium (secobarbital)" Lilly, Eli and Company, Indianapolis, IN.
- American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association; (1994):
- "Product Information. Nembutal Sodium (pentobarbital)" Abbott Pharmaceutical, Abbott Park, IL.
High Blood Pressure (Hypertension)
Moderate Potential Hazard, Moderate plausibility
dyphylline - cardiotoxicity
Like other methylxanthines, dyphylline at high dosages may be associated with positive inotropic and chronotropic effects on the heart. Therapy with dyphylline and products containing dyphylline should be administered cautiously in patients with severe cardiac disease, hypertension, hyperthyroidism, or recent myocardial infarction. The relationship between plasma dyphylline levels and therapeutic as well as toxic effects has not been determined.
- "Multum Information Services, Inc. Expert Review Panel"
- "Product Information. Lufyllin (dyphylline)" Wallace Laboratories, Cranbury, NJ.
Lufyllin-EPG (dyphylline / ephedrine / guaifenesin / phenobarbital) drug Interactions
There are 1334 drug interactions with Lufyllin-EPG (dyphylline / ephedrine / guaifenesin / phenobarbital)
Lufyllin-EPG (dyphylline / ephedrine / guaifenesin / phenobarbital) disease Interactions
There are 22 disease interactions with Lufyllin-EPG (dyphylline / ephedrine / guaifenesin / phenobarbital) which include:
- Acute Alcohol Intoxication
- Drug Dependence
- Liver Disease
- Respiratory Depression
- Prolonged Hypotension
- Renal Dysfunction
- Renal Dysfunction
- Cardiovascular Disease
- Suicidal Tendency
- Adrenal Insufficiency
- Hematologic Toxicity
- Paradoxical Reactions
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No information available.|
Do not stop taking any medications without consulting your healthcare provider.
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2018 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.